NA
NAN.AU Nanosonics Ltd
- Market cap
- AUD 906M
- P/E
- 50.5x
- P/B
- 4.17x
- ROE
- 8.2%
- Dividend yield
- -
- Fundamental score
- 2.0/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is NAN.AU undervalued?
Graham numberThe Graham number of Nanosonics Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nanosonics Ltd fundamental analysis
9 of 22 checks passedROE 0/2
Low return on equity (8.2%), below 10%.
ROA 1/1
Return on assets (5.7%) is above the industry median (-35.3%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-13.7%) is not above the 5-year average (15.5% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-13.7%) is below the industry median (24.9%).
Revenue Growth 1/2
Revenue grew 6.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (10.6%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 8.9x against interest expense, well covered.
PE vs Market 0/1
PE (50.5x) is above the market median (15.0x).
PE vs Industry 0/1
PE (50.5x) is above the industry median (36.4x).
PBV 0/1
Price to book (4.2x) is above the industry median (4.0x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 210.5, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 3.26, above 1.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Nanosonics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nanosonics Ltd
Nanosonics Limited engages in the manufacture and commercialization of infection control and decontamination products and related technologies in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. It offers trophon, an automated ultrasound probe high-level disinfection device built on hydrogen peroxide chemistry with integrated digital traceability solutions, as well as related consumables and accessories. The company also provides infec…
Full company profileNanosonics Ltd financial statements
Nanosonics Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 67.5M | 60.7M | 84.3M | 99.4M | 102M | 120M | 168M | 172M | 199M | 203M |
| Gross Profit | 50.2M | 45.3M | 62.8M | 71.1M | 74.9M | 86.2M | 126M | 134M | 156M | 149M |
| Operating Income | 13.1M | 2.81M | 13.7M | 11.7M | 8.38M | 792K | 18.0M | 9.12M | 8.93M | 15.0M |
| EBITDA | 15.2M | 7.14M | 19.2M | 16.7M | 15.7M | 7.86M | 29.5M | 21.7M | 31.8M | 23.7M |
| Net Income | 26.2M | 5.75M | 13.6M | 10.1M | 8.58M | 3.74M | 19.9M | 13.0M | 20.7M | 17.8M |
| EPS | 0.09 | 0.02 | 0.04 | 0.03 | 0.03 | 0.01 | 0.06 | 0.04 | 0.07 | 0.06 |
| Balance Sheet | ||||||||||
| Total Assets | 99.3M | 109M | 130M | 148M | 165M | 193M | 226M | 237M | 272M | 311M |
| Total Liabilities | 12.0M | 14.9M | 19.4M | 24.0M | 29.0M | 54.6M | 62.2M | 55.1M | 62.6M | 93.0M |
| Shareholders' Equity | 87.3M | 94.3M | 110M | 124M | 136M | 139M | 164M | 182M | 210M | 218M |
| Cash & Short-term Investments | 63.0M | 69.4M | 72.2M | 91.8M | 96.0M | 94.5M | 112M | 130M | 161M | 155M |
| Total Debt | 1.35M | 946K | 521K | 2.61M | 2.49M | 11.7M | 10.7M | 9.30M | 7.69M | 23.1M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 16.4M | 9.01M | 4.83M | 22.8M | 7.32M | 6.70M | 23.3M | 22.8M | 44.0M | 22.6M |
| Capital Expenditure | 1.07M | 2.31M | 1.68M | 1.94M | 1.38M | 6.97M | 3.57M | 2.52M | 8.72M | 5.14M |
| Free Cash Flow | 15.3M | 6.70M | 3.14M | 20.8M | 5.93M | -271K | 19.7M | 20.3M | 35.3M | 17.4M |
| Ratios | ||||||||||
| ROE | 30.0% | 6.1% | 12.4% | 8.2% | 6.3% | 2.7% | 12.1% | 7.1% | 9.8% | 8.2% |
| ROA | 26.4% | 5.3% | 10.5% | 6.8% | 5.2% | 1.9% | 8.8% | 5.5% | 7.6% | 5.7% |
| Net Profit Margin | 38.7% | 9.5% | 16.1% | 10.2% | 8.4% | 3.1% | 11.9% | 7.6% | 10.4% | 8.8% |
| Debt to Equity | 0.02x | 0.01x | 0.00x | 0.02x | 0.02x | 0.08x | 0.07x | 0.05x | 0.04x | 0.11x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nanosonics Ltd dividends
Nanosonics Ltd has not paid dividends in the last 10 fiscal years.
Who owns Nanosonics Ltd
- Insiders 8.46%
- Institutions 60.86%
- Public & others 30.68%
- Shares outstanding 299M
- Free float 274M
Top funds holding NAN.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Select Portfolios - Medical Technology & Devices Port | 21.8M | 7.24% | - | Feb 2021 |
| Vanguard International Stock Index-Total Intl Stock Indx | 3.74M | 1.24% | - | Oct 2020 |
| Fidelity Advisor Stock Selector Mid Cap Fund | 2.18M | 0.72% | - | Feb 2021 |
| Fidelity International Small Cap Fund | 1.89M | 0.63% | - | Jan 2021 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 1.50M | 0.50% | - | Dec 2020 |
| iShares Core MSCI EAFE ETF | 1.23M | 0.41% | - | Feb 2021 |
| iShares MSCI EAFE Small Cap ETF | 1.14M | 0.38% | - | Feb 2021 |
| Investment Managers Ser Tr-WCM International Small Cap Growth Fd | 903K | 0.30% | - | Jan 2021 |
| Wasatch International Opportunities Fund | 888K | 0.29% | - | Dec 2020 |
| Brinker Capital Destinations Tr-Destinations International Equity Fd | 691K | 0.23% | - | Nov 2020 |
Top institutions holding NAN.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Gofen & Glossberg LLC | 90.1K | 0.03% | - | Dec 2020 |
Nanosonics Ltd company profile
- Company name
- Nanosonics Ltd
- Ticker
- NAN.AU
- ISIN
- AU000000NAN9
- Exchange
- Australian Securities Exchange
- Listed since
- May 15, 2007
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 508
- Fiscal year end
- June
- Address
- Building A, Macquarie Park, NSW, Australia, 2113
- Phone
- 61 2 8063 1600
- Website
- nanosonics.com.au
About Nanosonics Ltd
Nanosonics Limited engages in the manufacture and commercialization of infection control and decontamination products and related technologies in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. It offers trophon, an automated ultrasound probe high-level disinfection device built on hydrogen peroxide chemistry with integrated digital traceability solutions, as well as related consumables and accessories. The company also provides infection control and decontamination products and related technologies. In addition, it is involved in the research, development, and commercialization of the CORIS system, an automated technology designed to transform flexible endoscope reprocessing. The company was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
Nanosonics Ltd management
10- Mr. Michael C. Kavanagh BSc, M.B.A.CEO, President, MD & Executive Director
- Mr. Jason Burriss B.Com., C.A.Chief Financial Officer
- Mr. Rod Lopez M.B.A.Chief Operating Officer
- Mr. Derek Minihane BSEE, J.D.Chief Technology Officer
- Mr. Sunny Pillai M.B.A.Chief Information Officer
- Mr. Jonathan Burdach Ph.D.Chief Medical Affairs & Scientific Officer
- Ms. Catherine StrongHead of Investor Relations & Corporate Communications
- Mr. Matthew Carbines B.Com., L.L.B.General Counsel & Company Secretary
- Ms. Kimberly Hill B.Sc.Chief Marketing Officer & Regional President of Asia Pacific
- Ms. Jodi Sampson M.A.I.C.D., M.B.A.Chief People & Culture Officer